Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Timolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.85 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | DRD1 | P21728 | 1/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timolol SCHEMBL26233 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL6828541 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL28427209 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL8093958 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL1588402 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL1428194 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL41823 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL30597567 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL365528 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL365527 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109546-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| WO-2000004898-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2000-02-03 | — | — | WO | claimed |
| US-4195085-A | Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate | MERCK & CO., INC. (US) | 1980-03-25 | — | — | US | claimed |
| US-12472273-B2 | Sterilization process of timolol gel forming solution through aseptic filtration | SENTISS PHARMA PRIVATE LIMITED (IN) | 2025-11-18 | — | — | US | disclosed |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230143595-A1 | A STERILIZATION PROCESS OF TIMOLOL GEL FORMING SOLUTION THROUGH ASEPTIC FILTRATION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| EP-4126076-A1 | A STERILIZATION PROCESS OF TIMOLOL GEL FORMING SOLUTION THROUGH ASEPTIC FILTRATION | Sentiss Pharma Private Limited (IN) | 2023-02-08 | — | — | EP | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021198911-A1 | A STERILIZATION PROCESS OF TIMOLOL GEL FORMING SOLUTION THROUGH ASEPTIC FILTRATION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2021-10-07 | — | — | WO | disclosed |
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2020-10-01 | — | — | US | disclosed |
| EP-0509752-B1 | Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist | MERCK & CO INC (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0448856-B1 | OPHTHALMIC PREPARATIONS COMPRISING TIMOLOL MALEATE | CHATFIELD PHARMACEUTICALS LIMITED (GB) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018124-A1 | OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF A CARBONIC ANHYDRASE INHIBITOR AND A β-ADRENERGIC ANTAGONIST | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0448856-A1 | Ophthalmic preparations comprising timolol maleate | CHATFIELD PHARMACEUTICALS LIMITED (GB) | 1991-10-02 | — | — | EP | disclosed |
| US-4238485-A | 1,2,5-THIADIAZOLE DERIVATIVE, THIAZIDE DIURETIC, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-12-09 | — | — | US | disclosed |
| US-4195085-A | Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate | MERCK & CO., INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4195085-A | Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate | MERCK & CO., INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4011217-A | B-ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | PDE6C, AGER, PDE6A | ADRB2 875/4885ADRB1 627/4885SMN1; SMN2 2863/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ADRB2 669/4885ADRB1 561/4885SMN1; SMN2 1501/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ADRB2 669/4885ADRB1 561/4885SMN1; SMN2 1501/4885 |
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | AGER, PDE6B, PTGER1 | ADRB2 185/4885ADRB1 59/4885SMN1; SMN2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.